Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.55 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978689 | 0.98 | CYP19A1 (0.53) | CYP19A1HMOX1L3MBTL1KDM4EMAPK1 | |
| SCHEMBL10289108 | 0.89 | HSP90AB1 (0.49) | CYP19A1HMOX1L3MBTL1KDM4EMAPK1 | |
| SCHEMBL31415785 | 0.85 | CYP19A1 (0.61) | CYP19A1 | |
| SCHEMBL10965028 | 0.82 | KDM4E (0.50) | CYP19A1HMOX1L3MBTL1KDM4EMAPK1 | |
| SCHEMBL23913862 | 0.82 | MAPK1 (0.53) | CYP19A1HMOX1L3MBTL1KDM4EMAPK1 | |
| SCHEMBL10066409 | 0.82 | MEN1 (0.54) | CYP19A1HMOX1L3MBTL1KDM4EMAPK1 | |
| SCHEMBL9584318 | 0.82 | KDM4E (0.49) | CYP19A1HMOX1L3MBTL1KDM4EMAPK1 | |
| SCHEMBL10053477 | 0.80 | MEN1 (0.53) | CYP19A1L3MBTL1KDM4EMAPK1MEN1 | |
| SCHEMBL708243 | 0.80 | KDM4E (0.51) | CYP19A1HMOX1L3MBTL1KDM4EMAPK1 | |
| SCHEMBL21708921 | 0.78 | ALDH1A1 (0.59) | HMOX1L3MBTL1KDM4EMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118909015-A | Special-shaped nucleoside dimer phosphoramidite and synthesis method thereof | 上海科泽永欣生物科技有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-1186332-C | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2005-01-26 | — | — | CN | claimed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | claimed |
| EP-0835252-A1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-04-15 | — | — | EP | claimed |
| CN-118909015-A | Special-shaped nucleoside dimer phosphoramidite and synthesis method thereof | 上海科泽永欣生物科技有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240276957-A1 | METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS | AGIOS PHARMACEUTICALS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11845767-B2 | Arginase inhibitors | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-12-19 | — | — | US | disclosed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116496326-A | Process for the preparation of oligomeric compounds | 南京金斯瑞生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | NOVARTIS AG (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20220251152-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-07-21 | — | — | US | disclosed |
| US-5278316-A | Indoles | WARNER-LAMBERT COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| CN-1064485-A | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME (GB) | 1992-09-16 | — | — | CN | disclosed |
| EP-0497512-A2 | Imidazole, triazole and tetrazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-08-05 | — | — | EP | disclosed |
| EP-0479910-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED Trp-Phe- AND PHENETHYLAMINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1992-04-15 | — | — | EP | disclosed |
| US-4992544-A | Intermediates for b-lactam antibiotics and b-lactamase inhibitor | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1991-02-12 | — | — | US | disclosed |
| WO-1991000274-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED TRP-PHE- AND PHENETHYLAMINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0405537-A1 | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives | WARNER-LAMBERT COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0114128-B1 | 3-AMINO-2-OXO-AZETIDINE DERIVATIVES CONTAINING IN POSITION 1 A NITROGEN HETEROCYCLIC RADICAL, PROCESS FOR THEIR PREPARATION, THEIR USE AS THERAPEUTICAL AGENTS AND INTERMEDIATES FOR THEIR PREPARATION | ROUSSEL-UCLAF (FR) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | ARG1, ARG2, ARGLU1 | CYP19A1 464/4885HMOX1 81/4885L3MBTL1 4661/4885 |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | CYP19A1 2482/4885HMOX1 512/4885L3MBTL1 646/4885 |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | HAVCR2, MICA, CD74 | CYP19A1 4729/4885HMOX1 3265/4885L3MBTL1 1143/4885 |
| US-11845767-B2 | Arginase inhibitors | ARG1, ARG2, ARGLU1 | CYP19A1 425/4885HMOX1 61/4885L3MBTL1 4634/4885 |
| US-20220251152-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | RPS27A, PSMG3, PREP | CYP19A1 3749/4885HMOX1 3021/4885L3MBTL1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.